MonicaMarieBertagnolliMD

General Surgery • Boston, MA

Surgical Oncology (Other than Breast)

Chief, Division of Surgical Oncology, Brigham and Women's Hospital Professor of Surgery, Harvard Medical School

Join to view full profile

Dr. Bertagnolli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bertagnolli's full profile

Already have an account?

Office
75 Francis St
Carrie Hall 116
Boston, MA 02115
Phone+1 617-732-6820

Fax+1 617-582-6177

Education & Training

Brigham and Women's HospitalResidency, Surgery, 1985 - 1989
University of Utah School of MedicineClass of 1985

Certifications & Licensure

MA State Medical License 1987 - 2027
WY State Medical License 2021 - 2025
NY State Medical License 1994 - 2001
American Board of Surgery Surgery

Awards, Honors, & Recognition

Boston Magazine Castle Connolly, 2010-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FACS) American College of Surgeons

Clinical Trials

Gene Testing in Patients With Colon Cancer Start of enrollment: 1998 Aug 01
Completed
Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps Start of enrollment: 2000 Mar 01
Completed
Phase 3
Genetic Study of Familial Factors in Patients With Colon Cancer Start of enrollment: 2001 Dec 01
Completed
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 Start of enrollment: 2007 Jul 01
Completed
Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC Start of enrollment: 2016 Mar 01
Completed
Phase 2
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer Start of enrollment: 2017 May 20
Terminated
Phase 2
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer Start of enrollment: 2016 Dec 01
Terminated
Phase 2
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer Start of enrollment: 2017 Mar 06
ACTIVE_NOT_RECRUITING
PHASE3
Atezolizumab Immunotherapy in Patients With Advanced NSCLC Start of enrollment: 2017 Nov 01
Completed
Phase 2
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma Start of enrollment: 2018 Sep 11
Active, not recruiting
Phase 2
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM Start of enrollment: 2020 Oct 21
Active, not recruiting
Phase 2
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer Start of enrollment: 2021 Mar 10
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy.
Akram Yazdani, Heinz-Josef Lenz, Gianluigi Pillonetto, Raul Mendez-Giraldez, Azam Yazdani
Communications Medicine. 2025-01-08
1 citations
The Oncology QCARD Initiative: Fostering efficient evaluation of initial real-world data proposals.
Donna R Rivera, Joy C Eckert, Carla Rodriguez-Watson, Catherine C Lerro, Monica M Bertagnolli
Pharmacoepidemiology and Drug Safety. 2024-11-01
6 citations
High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistance.
Yu-Hwa Huang, Charles H Yoon, Amit Gandhi, Thomas Hanley, Carlos Castrillon
Communications Medicine. 2024-07-02

Lectures

Presentation of the 2018 Public Service Award
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Individualized Breast, GYN, and Colon Cancer Management; New Data and Updates Relevant to Patient Care
Mayo School of Continuous Professional Development, Jacksonville, Florida - 2/15/2013

Press Mentions

National Institutes of Health Director Dr. Monica Bertagnolli QuitsJanuary 17th, 2025
NIH Director Steps DownJanuary 17th, 2025
ASCO Elects Dana-Farber/Brigham and Women's Elizabeth a. Mittendorf, MD, PhD, as 2026-2027 PresidentDecember 18th, 2024
Join now to see all

Grant Support

Acosog Competing RenewalNational Cancer Institute2012
Cancer And Leukemia Group BNational Cancer Institute2009–2012
Characterizing Disease And Treatment Response In Colon Cancer ChemopreventionNational Cancer Institute2008–2012
Advanced Training In Surgical OncologyNational Cancer Institute2011
Cancer And Leukemia Group B Human Specimen RepositoriesNational Cancer Institute2010–2011
Cancer And Leukemia Group B CCOP Research BaseNational Cancer Institute2010–2011
Phase II Clinical Trial Of Celecoxib (Or Nsaid) For Prevention Of Sporadic ColorNational Cancer Institute2007
Epithelial Homeostasis In APC Gene MutationNational Cancer Institute2000–2001
Phase II Clinical Trial Of Celecoxib (Or Nsaid)Division Of Cancer Prevention And Control1999–2000
Epithelial Homeostasis In APC Gene MutationNational Cancer Institute1997–1999